Nevertheless, these data also raise the question of whether enhancing circulating ANP concentrations with current antihypertensive agents (neprilysin inhibitors) may have added advantages in patients with hypertensive heart disease caused by volume-dependent hypertension. Here, NPPA is linked to hypertensive heart disease.